Response of collateral-dependent myocardium to vasopressin release during prolonged intense exercise.
We hypothesized that vasopressin concentrations during exercise attenuate the increase in collateral-dependent blood flow leading to left ventricular dysfunction in Ameroid-occluded miniswine. An Ameroid occluder was placed around the proximal left circumflex coronary artery (LCX) of 19 miniswine. Ten weeks later V1 receptor blockade with the use of [d(CH2)5Tyr-(Me)]arginine vasopressin (10-12 micrograms/kg iv) increased resting transmural flow (radioactive microspheres) in the LCX region, indicating the presence of V1 receptors. Neither injection of lysine vasopressin (125 pmol/kg) after V1 receptor blockade nor injection of two specific V2 receptor agonists caused changes in mean arterial pressure, heart rate, or left anterior descending coronary arterial flow velocity, indicating that V2 receptors mediate no appreciable vasodilation in the swine coronary circulation. Next the ratio of collateral to noncollateral flow and regional systolic wall thickening (sonomicrometer dimension gauges) were measured at rest and after 20 min of prolonged, intense treadmill exercise (85-90% of heart rate reserve) in the presence and absence of V1 receptor antagonism. This degree of exertion increased plasma lysine vasopressin from 6.2 +/- 1.0 at rest to 21.0 +/- 7.0 pg/ml (P < 0.05) during the unblocked run. However, the decrease in transmural blood flow ratio (collateral to noncollateral flow) from rest was similar during exercise before and after V1 receptor blockade (0.78 +/- 0.07 and 0.80 +/- 0.05, respectively; P < 0.05 vs. rest). Likewise, percent systolic wall thickening in the collateral-dependent region decreased from rest to exercise in the absence and presence of V1 receptor antagonism (35.9 +/- 4.5 and 39.5 +/- 3.8%, respectively; P < 0.05 vs. rest).(ABSTRACT TRUNCATED AT 250 WORDS)
Symons
J D
JD
Department of Internal Medicine, University of California, Davis 95616.
Longhurst
J C
JC
Stebbins
C L
CL
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001769:Blood; D001790:Blood Physiological Phenomena; D003097:Collateral Circulation / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003911:Dextrans / Q000494:pharmacology; D008236:Lypressin / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism*; D010805:Physical Conditioning, Animal; D005082:Physical Exertion; D017483:Receptors, Vasopressin / Q000378:metabolism; D013552:Swine; D013997:Time Factors; D014667:Vasopressins / Q000378:metabolism*
D065092:Antidiuretic Hormone Receptor Antagonists; D003911:Dextrans; D017483:Receptors, Vasopressin; D014667:Vasopressins; D008236:Lypressin